Cosmos Health

Cosmos Health EBIT per Employee

The EBIT per Employee of Cosmos Health (COSM) as of Oct 20, 2026 is -101,364.20 USD. In the previous year, EBIT per Employee was -93,071.79 USD — a change of 8.91% (lower).

EBIT per Employee

-101,364.20USD

YoY

8.91%

Last updated:

EBIT per Employee of Cosmos Health is 2025 -101,364.20 USD. EBIT per Employee of Cosmos Health was 2024 -93,071.79 USD. It decreases by 8.91% lower compared to the previous year.

The Cosmos Health EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-13,715.70 USD
Jan 1, 2019
-8,485.97 USD
Jan 1, 2020
16,652.10 USD
Jan 1, 2021
-27,812.29 USD
Jan 1, 2022
-45,852.98 USD
Jan 1, 2023
-133,933.85 USD
Jan 1, 2024
-93,071.79 USD
Jan 1, 2025
-101,364.20 USD
The Cosmos Health EBIT per Employee history
YEAREBIT per EmployeeYoY
-101,364.20USD+8.91%
-93,071.79USD-30.51%
-133,933.85USD+192.09%
-45,852.98USD+64.87%
-27,812.29USD-267.02%
16,652.10USD-296.23%
-8,485.97USD-38.13%
-13,715.70USD-51.07%
-28,033.24USD+1,059.11%
-2,418.51USD-10.90%
-2,714.47USD-106.22%
43,655.07USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmos Health Stock analysis

What does Cosmos Health do? Cosmos Health Inc generates revenue through the importation, exportation, distribution, and sale of branded pharmaceuticals, over-the-counter medicines, and generic pharmaceuticals. The company leverages its subsidiary Amplerissimo Ltd., which provides data mining, statistical data analysis, research, and consulting services including credit risk analysis, marketing management, and business management software consulting. SkyPharm S.A., a subsidiary of Amplerissimo, trades branded and generic pharmaceutical products across the European Union member states, contributing to the company's revenue streams. Clients include sectors requiring pharmaceutical distribution, consulting services, and EU market access for medicines. Amplerissimo's services target businesses needing data-driven insights, credit management, and strategic consulting, while SkyPharm serves the European pharmaceutical market with a focus on branded and generic products. The company's revenue model combines direct product sales with specialized consulting services, catering to both domestic and international clients in the pharmaceutical industry. This dual approach allows Cosmos Health Inc to address diverse market needs through its subsidiaries and core operations. The firm's primary buyers are pharmaceutical distributors, healthcare providers, and businesses seeking consulting services for market expansion, data analysis, and credit management. Amplerissimo's consulting services support clients in sectors requiring strategic planning, while SkyPharm's trading activities serve EU-based pharmaceutical companies and distributors. Cosmos Health Inc's revenue is derived from product sales and service contracts, with no mention of additional revenue streams beyond the described operations. Cosmos Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmos Health stock

EBIT per Employee of Cosmos Health is -101,364.20 USD in 2025.

EBIT per Employee of Cosmos Health changed from -93,071.79 USD to -101,364.20 USD, representing a 8.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Cosmos Health since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Cosmos Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Cosmos Health

All Key Metrics — Cosmos Health